Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.65 |
| ▸ | NPC1 | O15118 | 13/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.63 |
| ▸ | RELA | Q04206 | 2/20 | 0.63 |
| ▸ | CASP3 | P42574 | 3/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224873 | 0.80 | NPC1 (0.64) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL5174923 | 0.80 | NPC1 (0.84) | RAB9ANPC1MEN1KMT2AMAOB | |
| SCHEMBL6295679 | 0.79 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL108116 | 0.79 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2AMAOB | |
| SCHEMBL775160 | 0.79 | MAPT (0.56) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL27179668 | 0.78 | RAB9A (0.90) | RAB9ANPC1MEN1KMT2AMAOB | |
| SCHEMBL3199806 | 0.77 | PTPN1 (0.67) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL11238457 | 0.76 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AMAOB | |
| SCHEMBL3208598 | 0.76 | POLB (0.70) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13561178 | 0.76 | NPC1 (0.76) | RAB9ANPC1MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | RAB9A 3552/4885NPC1 2916/4885MEN1 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.